2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-149368
    SARS-CoV-2-IN-51
    		Inhibitor
    SARS-CoV-2-IN-51 (S-10) is a potent lead compound of Omicron fusion inhibitor. SARS-CoV-2-IN-51 inhibits Omicron and other variants with EC50s of 0.82-5.45 μM. SARS-CoV-2-IN-51 inhibits SARS-CoV-2 virus entry, by the direct interaction with S in the prefusion state.
    SARS-CoV-2-IN-51
  • HY-143417
    SARS-CoV-2-IN-16
    		Inhibitor
    SARS-CoV-2-IN-16 (Compound 12) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-16 exhibits potent anti-viral activity with the EC50 of 3.69 μM. SARS-CoV-2-IN-16 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-16 is a potent NPro ligand.
    SARS-CoV-2-IN-16
  • HY-154975
    SARS-CoV-2-IN-49
    		Inhibitor
    SARS-CoV-2-IN-49 is an irreversible covalent inhibitor of SARS-CoV-2 main protease.
    SARS-CoV-2-IN-49
  • HY-155540
    SARS-CoV-2 3CLpro-IN-14
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active SARS-CoV-2 3CLpro inhibitor. SARS-CoV-2 3CLpro-IN-14 shows significant anti-SARS-CoV-2 activity (EC50 = 0.18 μM) and low cytotoxicity (CC50 > 50 μM) in Vero E6 cells.
    SARS-CoV-2 3CLpro-IN-14
  • HY-B0462B
    (S)-Azelastine hydrochloride
    		Inhibitor
    (S)-Azelastine hydrochloride, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. (S)-Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
    (S)-Azelastine hydrochloride
  • HY-100211A
    (R)-TAPI-2
    		Control
    (R)-TAPI-2 is the isomer of TAPI-2 (HY-100211A). TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM), with an IC50 of 20 μM for MMP. TAPI-2 blocks the entry of infectious SARS-CoV.
    (R)-TAPI-2
  • HY-158405
    PAV-104
    		Inhibitor
    PAV-104 inhibits SARS-CoV-2 replication, with the MOI of 0.01. PAV-104 can interact with SARS-CoV-2 nucleocapsid (N) and interfered with its oligomerization, blocking particle assembly.
    PAV-104
  • HY-151608
    SARS-CoV-2 Mpro-IN-3
    		Inhibitor
    SARS-CoV-2 Mpro-IN-3 is a potent Mpro inhibitor with an IC50 value of ﹥5 μM. SARS-CoV-2 Mpro-IN-3 can be used in research of COVID-19.
    SARS-CoV-2 Mpro-IN-3
  • HY-146379
    SARS-CoV-2-IN-19
    		Inhibitor
    SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of SARS-CoV-2 with an EC50 of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases.
    SARS-CoV-2-IN-19
  • HY-168107
    SARS-CoV-2-IN-98
    		Inhibitor
    SARS-CoV-2-IN-98 (compound 38) is a SARS-CoV-2 inhibitor with the Kd of 0.73 μM and can be used for study of COVID-19.
    SARS-CoV-2-IN-98
  • HY-P10858
    UCI-1
    		Inhibitor
    UCI-1 is a SARS-CoV-2 main protease (Mpro) cyclic peptide inhibitor with an IC50 of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting Mpro. UCI-1 can be used in the study of anti-COVID-19 drugs.
    UCI-1
  • HY-N0752R
    Scutellarein (Standard)
    		Inhibitor
    Scutellarein (Standard) is the analytical standard of Scutellarein. This product is intended for research and analytical applications. Scutellarein is a natural flavonoid compound with anti-inflammatory effects.
    Scutellarein (Standard)
  • HY-100701
    Dutacatib
    		Inhibitor
    Dutacatib is inhibitor for SARS-CoV-2 3CLpro and cathepsin K, which exhibits antiviral activity and ameliorates the cancer-induced bone diseases.
    Dutacatib
  • HY-162914
    SARS-CoV-2-IN-96
    		Inhibitor
    SARS-CoV-2-IN-96 (compound 12b) is an inhibitor of HCoV-OC43 (EC50= 97 nM) and SARS-CoV-2 (EC50= 45 nM) and low cytotoxicity (CC50> 10 μM) in Huh7 cells.
    SARS-CoV-2-IN-96
  • HY-151478
    SARS-CoV-2-IN-33
    		Inhibitor
    SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 main protease (Mpro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19.
    SARS-CoV-2-IN-33
  • HY-156008
    SARS-CoV-2-IN-58
    		Inhibitor
    SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent against SARS-CoV-2 (EC50: 18 μM). SARS-CoV-2-IN-58 inhibits SARS-CoV-2 Mpro with an IC50 of 0.35 μM.
    SARS-CoV-2-IN-58
  • HY-14648S1
    Dexamethasone-d5-1
    		Inhibitor
    Dexamethasone-d5-1 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d<sub>5</sub>-1
  • HY-B0402R1
    Amantadine in Methanol (Standard)
    		Inhibitor
    Amantadine in Methanol (Standard) is the solution of Amantadine (Standard). This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research[4].
    Amantadine in Methanol (Standard)
  • HY-158422
    SARS-CoV-2 Mpro-IN-16
    		Inhibitor
    SARS-CoV-2 Mpro-IN-16 (compound 5J) is a SARS-CoV-2 Mpro inhibitor, and inhibits HEK293 cells growth.
    SARS-CoV-2 Mpro-IN-16
  • HY-B0180S1
    Imiquimod-d9
    		Inhibitor
    Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
    Imiquimod-d<sub>9</sub>
Cat. No. Product Name / Synonyms Species Source